Actinium Pharmaceuticals, Inc. (ATNM) stock analysis

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/3080% below fair value

$1.59+0.00 (0.00%)

Close on Nov 12, 2026Market cap $49.99MP/E 4.4Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Mixed10 of 30 checks passed

Actinium Pharmaceuticals passes 10 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation: 4/6
Growth: 0/6
Past performance: 1/6
Financial health: 5/6
Dividend: 0/6

What stands out

Margin of safety over 20%
The price is 79.7% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $1.59 is below our fair value estimate of $7.84.
No debt
Actinium Pharmaceuticals has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.

What to watch

Return on equity under 15%
Return on equity was 45.9% over the last twelve months and averaged -91.3% over five years; we look for 15% on both.
Revenue growing under 10% a year
Revenue grew -55.6% a year over the last three fiscal years, short of the 10% we look for.
Elevated bankruptcy risk
The Altman Z-score is -8.82; above 3 is the safe zone and below 1.8 the distress zone.
No dividend
Actinium Pharmaceuticals has not paid a dividend in the last twelve months.

Valuation4/6

P/E against its history
Not enough price and earnings history to compare.
P/E below the industry
Actinium Pharmaceuticals's P/E of 4.4 is below the Drugs median of 25.1.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
Actinium Pharmaceuticals's price-to-book of 1.65 is below the Drugs median of 2.29.
Trading below fair value
The share price of $1.59 is below our fair value estimate of $7.84.
Margin of safety over 20%
The price is 79.7% below fair value, more than the 20% cushion we look for.

Growth0/6

Revenue growing under 10% a year
Revenue grew -55.6% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.

Past performance1/6

Return on equity under 15%
Return on equity was 45.9% over the last twelve months and averaged -91.3% over five years; we look for 15% on both.
Return on invested capital
Needs operating income and invested capital.
Return on equity above the industry
Actinium Pharmaceuticals's return on equity of 45.9% is above the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.

Financial health5/6

No debt
Actinium Pharmaceuticals has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 4.08 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -8.82; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

No dividend
Actinium Pharmaceuticals has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$7.84

The share price is 80% below this estimate.

20%+ below

Near fair value

20%+ above

$1.59Price$7.84Fair value

Method	Multiple used	Own 5Y median	Industry median	Value per share	Weight
P/E	25.1×	–	25.1×	$9.03	53%
EV/EBITDA	17.1×	–	17.1×	$6.47	47%
Fair value				$7.84	100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

P/B at month end
Own 5-year median 2.7
Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day: $304.18K
Value traded per 1% price move: $40.56K

Downside

Medium risk

Typical loss in a bad month: 22.1%
Volatility (annualized): 74%
Sharpe ratio, 1 year: 0.20
Beta to the S&P 500 (5Y): 1.09

Typical bad-month loss, week by week

Margins

Share of revenue, fiscal years 2011 to 2025

Operating margin

-40274.4%

Net margin

-37652.2%

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	–	-55.6%	–	–

Returns and balance sheet

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	-121.7%	-66.4%	-167.0%
Return on assets	-99.0%	-56.9%	-52.7%
Current ratio	4.95	13.62	6.20
Capex to revenue	–	–	115.6%
Diluted shares	2M	12M	31M

DuPont analysis

Return on equity split into margin, efficiency and leverage

Net margin-37652.2%

Asset turnover0.00×

Equity multiplier3.17×

Return on equity, FY2025-167.0%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	-37652.2%	0.00×	3.17×	-167.0%
FY2023	-60269.1%	0.00×	1.90×	-94.9%
FY2022	-3205.5%	0.01×	1.39×	-47.2%
FY2021	-2165.6%	0.02×	1.09×	-36.7%

Where these numbers come from

Parsed from the XBRL in Actinium Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Aug 11, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing